Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade C 53.78 -0.61% -0.33
SGEN closed down 0.61 percent on Thursday, February 22, 2018, on 73 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
1 Watcher
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical SGEN trend table...

Date Alert Name Type % Chg
Feb 22 Fell Below 50 DMA Bearish 0.00%
Feb 21 50 DMA Support Bullish -0.61%
Feb 21 NR7 Range Contraction -0.61%
Feb 21 Inside Day Range Contraction -0.61%
Feb 21 Wide Bands Range Expansion -0.61%
Feb 20 50 DMA Support Bullish -0.70%
Feb 20 Wide Bands Range Expansion -0.70%
Feb 16 Doji - Bearish? Reversal -2.09%
Feb 16 Wide Bands Range Expansion -2.09%
Feb 16 Up 3 Days in a Row Strength -2.09%

Older signals for SGEN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Is SGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 71.32
52 Week Low 45.31
Average Volume 1,270,021
200-Day Moving Average 56.1857
50-Day Moving Average 53.9859
20-Day Moving Average 53.926
10-Day Moving Average 53.103
Average True Range 2.0465
ADX 11.98
+DI 22.62
-DI 23.42
Chandelier Exit (Long, 3 ATRs ) 51.7705
Chandelier Exit (Short, 3 ATRs ) 54.9195
Upper Bollinger Band 57.5847
Lower Bollinger Band 50.2673
Percent B (%b) 0.48
BandWidth 13.569336
MACD Line -0.1814
MACD Signal Line -0.3442
MACD Histogram 0.1628
Fundamentals Value
Market Cap 7.69 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -37.61
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.12
Resistance 3 (R3) 56.30 55.70 55.73
Resistance 2 (R2) 55.70 55.10 55.61 55.60
Resistance 1 (R1) 54.74 54.74 54.44 54.56 55.47
Pivot Point 54.14 54.14 53.99 54.05 54.14
Support 1 (S1) 53.18 53.54 52.88 53.00 52.09
Support 2 (S2) 52.58 53.18 52.49 51.96
Support 3 (S3) 51.62 52.58 51.83
Support 4 (S4) 51.44